Spectrum Pharma sells marketed portfolio for $160 million upfront, up to $140 million in milestone payments

Spectrum Pharmaceuticals Inc. said Thursday it has reached an agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C. Spectrum said it will receive $160 million in an upfront cash payment and be entitled to up to $140 million milestone payments on reaching certain regulatory and sales goals. The company said its staff will be reduced by about 40% with most transitioning to Acrotech. The remaining staff will focus on the launch of it two late-stage pipeline treatments, ROLONTIS and poziotinib, which are cancer drugs. Shares were halted for the news, but have fallen 46.1% in the last 12 months, while the S&P 500 has fallen 6.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.